Oncolys Submits IND For Anti-HIV Drug Festinavir
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Oncolys BioPharma submitted an Investigative New Drug application for anti-HIV drugFestinavir (OBP-601) to the U.S. FDA, to gain permission to initiate Phase I trials. Festinavir is a novel anti-HIV drug with a mechanism for inhibiting nucleotide reverse transcriptase, which is essential for human immune-deficiency virus replication. Based on preclinical studies, Festinavirshows comparable or superior efficacy and safety versus existing NRTIs and could become a potential best-in-class drug for combination in a highly active antiretroviral therapy. Oncolys in-licensed worldwide rights to Festinavir from Yale University in June 2006. (Click here for more-J apanese language
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.